Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

heart attack patients

- PMLiVE

AZ’s COVID-19 vaccine demonstrates efficacy rate of up to 90%

Across two dosing regimens, vaccine has average efficacy of 70%

- PMLiVE

Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer

Drug approved in combination with Merck's KGaA's Erbitux

- PMLiVE

Chief investigator of Oxford Vaccine Group says data could be released before Christmas

AstraZeneca is developing a COVID-19 vaccine with Oxford University

- PMLiVE

AZ’s COVID-19 vaccine proves promising in elderly participants, new data shows

Immune responses were similar in younger and older adults

- PMLiVE

AZ’s BTK inhibitor Calquence fails in COVID-19 study

Therapy is already approved to treat a number of blood cancers

- PMLiVE

AZ, Amgen’s investigational asthma drug comes good in phase 3

Tezepelumab evaluated in late-stage trial of severe asthma patients

- PMLiVE

NICE launches consultation on its methods of drug evaluation

Public consultation launched on Friday 6 November

- PMLiVE

AZ is expecting late-stage COVID-19 vaccine data this year

Company reiterated timeline in third quarter results

- PMLiVE

NICE – but not enough

Why evidence is better than assumption when executing commercial strategy

AstraZeneca AZ

AZ confirms the UK’s MHRA has started rolling review of its COVID-19 vaccine

Regulatory agency will review data as and when it becomes available

AstraZeneca AZ

AZ’s COVID-19 vaccine shows promise in younger and older adults

Company said vaccine produces similar immune response in younger and older adults

- PMLiVE

Both AZ and J&J set to resume US COVID-19 vaccine trials

Both companies paused their trials after separate participant illness events

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links